Method of treating anemia using long-acting EPO formulation
US11524054B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jan 8, 2016 |
| Grant date | Dec 13, 2022 |
| Priority date | — |
| Expiry date | Jan 8, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/46
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a method for treating anemia using a long-acting EPO formulation, and more specifically, a method for treating patients with anemia by confirmation of safe, long-acting, and optimal effective dosage and usage in administering a fusion polypeptide which comprises an EPO and an immunoglobulin hybrid Fc to patients with anemia. The method of administering the fusion polypeptide employs an appropriate dosage and usage which not only shows an excellent long-acting property compared to the existing EPO products but also minimizes cardiovascular side effects that may occur due to a rapid increase in hemoglobin level, which is an effect of anemia treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.